Introduction: The aim of this study was to investigate the efficacy of resveratrol and octreotide, agents that are used to prevent intra-abdominal adhesions in experimental models, in preventing intraperitoneal adhesions when used alone or in combination. Materials and Methods: The study employed 28 young female Wistar albino rats weighing 250-300 grams. An experimental adhesion model was created in each rat using serosal abrasion and peritoneal excision. They were divided into four groups, each comprising seven rats: Group 1, adhesion induction only; Group 2, resveratrol administration only; Group 3, octreotide administration only; and Group 4, administration of resveratrol and octreotide combination. The rats were monitored under appropriate conditions for 14 days and then underwent laparotomy. Macroscopic intensity and extensiveness of adhesions and microscopic changes in the granulation tissue (cellular intensity, reticular and collagen fibers, capillaries, elastic and smooth muscle fibers, fibrosis) were evaluated and graded. Kruskal-Wallis and Mann-Whitney U-test were used in statistical analysis and the level of statistical significance was established as p <0.05. Results: There was no significant difference between the groups in terms of the intensity and extensiveness of macroscopic adhesions (p=0.377 and p=0.319). There was a statistically significant difference between the microscopic scores of the groups according to Zühlke’s classification (p=0.026). The Bonferroni correction used to test for the differences revealed that the rats in Group 1 achieved significantly higher scores than the rats in Group 3 (p=0.016). Conclusion: Octreotide showed higher efficiency compared to the control group in microscopic classification; however, the two agents were not superior to each other or their combination was not superior in preventing intra-abdominal adhesions.
Octreotide ; resveratrol

This study was conducted to compare the efficacy of sandostatine with vasopressin in hemoptitis due to pulmonary tuberculosis. In general, the control rate of bleeding in sandostatine group was better than that in the vasopressin group. As shown in angiography, 2-5 minutes after injection of 0.05 mg of sandostatine, bronchial arteries, which were largely dilated in hemoptitis, are spectacularly constricted. Sandostatine had also fewer side effects than those of vasopressine
Tuberculosis, Pulmonary ; Octreotide ; Hemoptysis

No abstract available.
Acromegaly* ; Octreotide* ; Somatostatin*

Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant disease caused by a mutation in the MEN1 gene. We present a 65-year-old man with MEN1 who has primary hyperparathyroidism, microprolactinoma, meningioma and gastrinoma. He had undergone parathyroidectomy followed by tumour excision of meningioma. The duodenal gastrinoma lesion was inoperable as it was close to the superior mesenteric artery with high surgery risk. Medical therapy with octreotide LAR had been initiated and showed good biochemical response as well as disease progression control. Chemoembolization was proposed if the duodenum lesion reduces in size on maintenance treatment with octreotide LAR. This case highlights the challenges in managing this rare condition and octreotide LAR has shown to be effective in controlling the disease progression in MEN1 with inoperable gastrinoma
meningioma ; octreotide ; gastrinoma

No abstract available.
Humans ; Octreotide ; Peptides, Cyclic ; Somatostatin

No abstract available.
Humans ; Octreotide ; Peptides, Cyclic ; Somatostatin

Somatostatin analogue octreotide is commonly used for the treatment of carcinoid syndrome. Octreotide also has an antiproliferative effect in neuroendocrine tumors and has demonstrated tumor reduction in patients having advanced carcinoid tumor. This is a case report of a patient who had metastatic liver carcinoid tumor and showed marked regression of liver metastasis after octreotide therapy.
Carcinoid Tumor* ; Humans ; Liver ; Neoplasm Metastasis ; Neuroendocrine Tumors ; Octreotide* ; Somatostatin

PURPOSE: Octreotide, a potent synthetic somatostatin (SM) analogue, was recently evaluated and found to have a beneficial effect in thyroid eye disease (TED). Lanreotide (LRT: Somatuline(R)), a new SM analogue, is more active and has a much longer duration of action. The aim of this study was to report the therapeutic effect of LRT on the treatment of TED. METHODS: Four patients of mean age 42.5 years had severe acute thyroid-related ophthalmopathy symptoms. The NOSPECS system was applied in this study to evaluate the response to treatment. They received 40 mg LRT i.m. every 2 weeks over a period of 3 months. RESULTS: All of them showed a significant improvement of acute inflammatory symptoms in both eyes. The average of TED score was 3.6, while it was 6.3 before the injection. Average clinical activity score of pre-injection was 4.1 and it markedly decreased to 1.3, and the self assessment score was 1.4, which means a moderate satisfaction. The amount of proptosis was found to decrease about 3.0 mm. CONCLUSIONS: We report our clinical experience that LRT has a beneficial effect on active TED and it is a good therapeutic modality for medical treatment.
Exophthalmos ; Eye Diseases ; Humans ; Octreotide ; Self-Assessment ; Somatostatin ; Thyroid Gland*

Chylothorax is a rare complication following cardiac surgery for congenital heart diseases. Although conservative management is successful in the majority of cases, surgical intervention is required in a refractory one. Recently, subcutaneous or intravenous infusion of octreotide has been used as a safe treatment that helps avoiding surgical intervention. Herein, we report two cases of postoperative chylothorax treated with parenteral octreotide and conservative therapy.
Chylothorax* ; Heart Diseases ; Infusions, Intravenous ; Octreotide* ; Postoperative Complications ; Thoracic Surgery

The treatment of choice for Cushing's disease is surgical removal of tumor, the source of ACTH overproduction. In occasional patients in whom a surgical approach including total adrenalectomy is not feasible or surgical removal of tumor is not complete, medical treatment may be necessary because pituitary irradiation requires a long 1ag time to remission. Although ketoconazole, an imidazole derivative with inhibitory activity on adrenal steroidogenesis has been reported to be effective in the treatment of Cushing's disease, the limited effectiveness in lowering very high level of cortisol and occasional hepatotoxicity restrains its wide use. In this report, we describe a woman with Cushing's disease due to pituitary microadenoma. Transsphenoidal pituitary adenomeetomy followed by ketoconzole treatment had been unsuccessful in achieving remission of the disease, but combined treatment with ketoconazole and octreotide accomplished successful reduction in cortisol production.
Adrenalectomy ; Adrenocorticotropic Hormone ; Female ; Humans ; Hydrocortisone ; Ketoconazole* ; Octreotide* ; Pituitary Irradiation